Wells Fargo & Company MN Grows Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Wells Fargo & Company MN increased its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 106.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,415 shares of the company’s stock after acquiring an additional 3,828 shares during the period. Wells Fargo & Company MN’s holdings in Jasper Therapeutics were worth $159,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. EntryPoint Capital LLC purchased a new position in Jasper Therapeutics in the 4th quarter worth approximately $223,000. Jane Street Group LLC bought a new position in shares of Jasper Therapeutics in the third quarter worth approximately $251,000. Barclays PLC increased its stake in shares of Jasper Therapeutics by 320.7% in the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after buying an additional 12,308 shares during the period. JPMorgan Chase & Co. raised its holdings in Jasper Therapeutics by 239.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock valued at $308,000 after buying an additional 11,567 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Jasper Therapeutics by 12.6% during the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock valued at $316,000 after buying an additional 1,652 shares during the period. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Stock Performance

JSPR stock opened at $4.52 on Friday. The company has a market capitalization of $67.90 million, a price-to-earnings ratio of -0.95 and a beta of 2.74. The business’s 50 day moving average price is $4.66 and its two-hundred day moving average price is $11.55. Jasper Therapeutics, Inc. has a fifty-two week low of $3.13 and a fifty-two week high of $26.84.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). Sell-side analysts forecast that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on JSPR shares. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. UBS Group started coverage on Jasper Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $38.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $62.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.